📰 Immunic Decided News
Immunic Decided News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Immunic Decided. Real-time updates on events, politics, business and more.
April 5, 2023
– 50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calcium as Compared to Placebo – – 30 mg Once-Daily Dose of...
April 5, 2023
Issuer: Immunic, Inc. / Key word(s): Study results/Strategic Company Decision Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe
April 5, 2023
Issuer: Immunic, Inc. / Key word(s): Study results/Strategic Company Decision Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis 05.04.2023 / 12:30 CET/CEST The issuer is solely responsible for the cont...